Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis

Oncology Letters

Volumn 5, Issue 6, 2013, Pages 1915-1920

  Chen, Peng ^a   Wang, Long ^b   Li, Hao ^a   Liu, Bing ^c   Zou, Zui ^d  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^c AIR FORCE GENERAL HOSPITAL   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced cancer; Cetuximab; Hypomagnesemia; Meta analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO;

ADVANCED CANCER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL ASSESSMENT; COLORECTAL CANCER; DISEASE ASSOCIATION; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLISHING; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 84876483964     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1301     Document Type: Article

References (33)

1. Milano G, Spano JP and Leyland-Jones B: EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer 99: 1-5, 2008.
2. Heist RS and Christiani D: EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10: 59-68, 2009.
3. Brandes AA, Franceschi E, Tosoni A, Hegi ME and Stupp R: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14: 957-960, 2008.
4. Reynolds NA and Wagstaff AJ: Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 64: 109-121, 2004.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
6. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W and Zielinski CC: Cetuximab plus FOLFOX6 or FOLFIRI in meta-static colorectal cancer: CECOG trial. World J Gastroenterol 16: 3133-3143, 2010.
7. Chen P, Wang L, Liu B, Zhang HZ, Liu HC and Zou Z: EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 67: 235-243, 2011.
8. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T and Biron P: Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14: 636-643, 1996.
9. Crawford J, Dale DC and Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100: 228-237, 2004.
10. Fakih MG, Wilding G and Lombardo J: Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6: 152-156, 2006.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
12. Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M and Hinoda Y: The importance of evaluation of DNA amplify-ability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol 41: 165-171, 2011.
13. Wu L, Parton A, Lu L, Adams M, Schafer P and Bartlett JB: Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 60: 61-73, 2011.
14. Burtness B, Goldwasser MA, Flood W, Mattar B and Forastiere AA; Eastern Cooperative Onclogy Group: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005.
15. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR and Woytowitz D: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28: 911-917, 2010.
16. Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, Kaplan RS and Maughan TS: Toxicity associated with combination oxaliplatin plus fuoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100: 251-258, 2009.
17. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA: EPIC: phase III trial of cetuximab plus irinotecan after fuoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319, 2008.
18. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR and Shepherd FA: Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25: 5777-5784, 2007.
19. Jonker DJ, O'Callaghang CJ, Karapetis CS, Zalcberg JR, Tu D, Au H J, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C and Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
20. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N and Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Me d 359: 1116-1127, 2008.
21. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF and Punt CJ: A randomised phase III study on capecitabine, oxali-platin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19: 734-738, 2008.
22. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A and Goldberg RM: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307: 1383-1393, 2012.
23. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson R H, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R and Cheadle JP; MRC COIN Trial Investigators: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114, 2011.
24. Schrag D, Chung KY, Flombaum C and Saltz L: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97: 1221-1224, 2005.
25. Touyz RM: Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. Am J Physiol Heart Circ Physiol 294: H1103-H1118, 2008.
26. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R and Sheffeld VC: Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31: 171-174, 2002.
27. Schlingmann K P, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW and Konrad M: Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 31: 166-170, 2002.
28. Groenestege WM, Thébault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV and Bindels RJ: Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomag-nesemia. J Clin Invest 117: 2260-2267, 2007.
29. Vincenzi B, Santini D and Tonini G: Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. Expert Opin Pharmacother 9: 1267-1269, 2008.
30. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M and Barni S: Risk of anti-EGFR monoclonal antibody-related hypomag-nesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11 (Suppl 1): S9-S19, 2012.
31. Lau J, Ioannidis JP and Schmid CH: Summing up evidence: one answer is not always enough. Lancet 351: 123-127, 1998.
32. Thompson SG: Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309: 1351-1355, 1994
33. Higgins J, Thompson S, Deeks J and Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 7: 51-61, 2002.